FoRx Therapeutics is a biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress pathways.
FoRx Therapeutics has raised €53M across 2 funding rounds from 4 investors, most recently a Series A round in Dec 2025. Based in Basel, Switzerland; founded 2019; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2025-12-19 | Series A | €43M | EQT Life Sciences,M Ventures,Novartis Venture Fund,Pfizer Ventures | View deal → |
| 2020-04-22 | Seed | €10M | M Ventures | View deal → |
